The DyeVert™ Contrast Modulation System is to be used for the controlled infusion and contrast volume reduction of radiopaque contrast media for angiographic procedures with the following agents: Iodixanol 270 or 320 mg/mL, Iohexol 300 or 350 mgI/mL and Iopamidol 370 mgI/mL.

Device Description

The Osprey Medical DyeVert™ Contrast Modulation System provides a second fluid pathway that modifies the overall system resistance as experienced during the physician's manual injection and allows for excess (i.e. contrast that is not needed for diagnostic or therapeutic purposes) contrast media to be diverted into a reservoir and away from the patient while maintaining adequate image quality. Excess contrast is typically a result of refluxed contrast within the patient's vasculature, retrograde to the desired image area. The DyeVert™ System allows for the modulated reduction of contrast media during manual injections in coronary or peripheral imaging procedures. The DyeVert™ System is a device for physician utilization during efforts to minimize total patient contrast volumes.

The DyeVert™ System consists of a sterile, single-use, fully-disposable apparatus. The source contrast container is connected to the reservoir chamber which has one tube directing contrast (through the manifold) to refill the injection syringe upon aspiration with preference to the diverted contrast volume prior to aspiration from the contrast source.

AI/ML Overview

The provided text describes the DyeVert Contrast Modulation System and references a clinical study for its effectiveness. However, it does not provide the detailed acceptance criteria or the specific study that proves the device meets those criteria in the format requested (e.g., a table with acceptance criteria and reported performance metrics).

The document is a 510(k) summary for a medical device and focuses on demonstrating substantial equivalence to a predicate device, rather than presenting a standalone performance study with detailed acceptance criteria. While it mentions a clinical trial, the information provided about that trial is limited and not structured to answer all aspects of your request.

Here's a breakdown of what can be extracted and what information is missing based on your prompt:

1. A table of acceptance criteria and the reported device performance

Missing. The document does not provide explicit numerically stated acceptance criteria for key performance indicators (like minimum percentage contrast reduction, or maximum acceptable image quality degradation). It states "All testing passed and demonstrated product performance met all prior established acceptance criteria" for non-clinical tests, but these criteria are not detailed. For the clinical study, it reports a "mean reduction of 15.4% with a corresponding t-test p value of 0.0229" and "15.0% relative reduction." It also mentions "maintaining adequate image quality" and "one incident recorded as poor image quality... <1%". However, these are reported results, not pre-defined acceptance criteria presented in a table format.

2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)

Test Set Sample Size: "For the sample size of 147 patients (treatment group)". It also mentions "control group" but doesn't explicitly state its size.
Data Provenance: "A prospective, randomized, multi-center clinical evaluation was conducted using the Osprey Medical AVERT™ Contrast Modulation System."
Country of Origin: Not specified in the provided text.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)

Missing. The document mentions "maintaining adequate image quality" and "adeqate opacity," but does not explicitly describe how image quality was assessed (e.g., by experts, automated systems) or the number/qualifications of any such experts.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

Missing. No information on adjudication methods for image quality, adverse events, or any other outcome is provided.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not Applicable / Missing. This device is a physical system for modulating contrast, not an AI or imaging diagnostic tool that would typically involve a multi-reader multi-case study for human reader improvement with AI. The document notes that "one incident recorded as poor image quality related to the treatment device that resulted in the system being 'shut off'," but this is not about human reader performance with AI assistance.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not Applicable. This is a physical device, not a software algorithm. Its performance is inherent in its mechanical function.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Contrast Volume Reduction: Measured directly as the primary effectiveness endpoint. This is an objective measurement.
Image Quality: Assessed to be "adequate" with a "low prevalence (<1%)" of poor image quality. The methodology for this assessment (e.g., expert review, objective metrics) is not detailed, so the "ground truth" method for image quality is unclear.
Adverse Events: Clinical outcomes data derived from the study.

8. The sample size for the training set

Not Applicable. This is a physical device, not an AI model requiring a training set in the typical sense. The "training" would refer to manufacturing and validation processes, not data to train an algorithm.

9. How the ground truth for the training set was established

Not Applicable. See point 8.

Summary of available information regarding the clinical study (leverage from the AVERT™ System):

Study Type: Prospective, randomized, multi-center clinical evaluation.
Device Studied: Osprey Medical AVERT™ Contrast Modulation System (clinical data leveraged for DyeVert due to high-level similarities and bench testing).
Participants: Male and female subjects 18 years and older who were candidates for therapeutic percutaneous coronary intervention (PCI) procedures with documented chronic kidney disease.
Primary Effectiveness Endpoint: Demonstrate a mean reduction of contrast volume in the treatment group compared to the standard of care control group.
Results:
- Mean reduction of 15.4% with a t-test p-value of 0.0229.
- 15.0% relative reduction of contrast volume between treatment and control groups.
- Diagnostic angiographic procedures demonstrated a 20.6% relative reduction.
- PCI angiographic procedures demonstrated a 17.2% relative reduction.
- One incident of poor image quality related to the device (<1%).
- No reported device-related or unanticipated adverse events.

To fulfill your request completely, you would need a source document directly detailing the clinical trial, including its protocol, statistical analysis plan, and detailed results, which is beyond what is provided in this 510(k) summary.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the circumference. Inside the circle is a stylized emblem featuring three human profiles facing to the right, stacked on top of each other, with flowing lines suggesting movement or connection.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

February 4, 2016

Osprey Medical, Inc. Melanie Hess Vice President, Regulatory Affairs 5600 Rowland Road Suite 250 Minnetonka, Minnesota 55343

Re: K153141

Trade/Device Name: DyeVert Contrast Modulation System Regulation Number: 21 CFR 870.1650 Regulation Name: Angiographic Injector and Syringe Regulatory Class: Class II Product Code: DXT Dated: December 22, 2015 Received: December 23, 2015

Dear Melanie Hess:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

K153141

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) TBD

Device Name

DyeVert Contrast Modulation System

Indications for Use (Describe)

The DyeVert™ Contrast Modulation System is to be used for the controlled infusion and contrast volume reduction of radiopaque contrast media for angiographic procedures with the following agents: Iodixanol 270 or 320 mg/mL. Iohexol 300 or 350 mgI/mL and Iopamidol 370 mgI/mL.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below.

{3}------------------------------------------------

510(k) Summary

510(k) Summary As required by 21CFR 807.92(c)

510(k) Number:	K153141
Date Prepared:	November 02, 2015
Submitter's Name/Address:	Osprey Medical5600 Rowland Road Suite 250Minnetonka, MN 55343
Contact Person:	Melanie HessVice President, Regulatory AffairsTel: 952-955-8252Fax: 952-955-8171Mhess@ospreymed.com

Device Information:

Trade Name/Proprietary Name:	DveVert™ Contrast Modulation System
Manufacturer:	Osprey Medical, Inc.
Common Name:	Injector and Syringe, Angiographic
Classification Registration:	21 CFR § 870.1650
Product Code:	DXT
FDA Center/Branch:	CDRH/Interventional Cardiology Devices Branch (ICDB)

Device Description:

{4}------------------------------------------------

coronary or peripheral imaging procedures. The DyeVert™ System is a device for physician utilization during efforts to minimize total patient contrast volumes.

Intended Use:

The DyeVert™ Contrast Modulation System is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures.

Indications for Use:

The DyeVert™ Contrast Modulation System is to be used for the controlled infusion and contrast volume reduction of radiopaque contrast media for angiographic procedures with the following agents: Iodixanol 270 or 320 mgl/mL, Iohexol 300 or 350 mgVmL and Iopamidol 370 mgVmL.

Primary Predicate Device:

Trade Name/Proprietary Name:	DyeVert™ Contrast Modulation System
Manufacturer:	Osprey Medical, Inc.
Common Name:	Injector and Syringe, Angiographic
Classification:	II
CFR Reference:	21 CFR § 870.1650
Product Code:	DXT
510(k) number(s):	K151746

Secondary Predicate Device:

Trade Name/Proprietary Name:	AVERT™ Contrast Modulation System
Manufacturer:	Osprey Medical, Inc.
Common Name:	Injector and Syringe, Angiographic
Classification:	II
CFR Reference:	21 CFR § 870.1650

{5}------------------------------------------------

Product Code:	DXT
510(k) number(s)	K151300

Comparison to the Predicate Device:

The DyeVert Contrast Modulation System is substantially equivalent to the previously cleared DyeVert and AVERT Contrast Modulation Systems, K151746 and K151300 respectively, in that they are both designed to control the infusion of radiopaque contrast media for angiographic procedures.

The proposed DyeVert™ System and predicate DyeVert™ System are identical systems with the exception of the labeling modification in accordance with clinical trial data and an additional model number for use with low viscosity contrast as indicated in the labeling.

. The proposed device consists of the same material and technical characteristics; and
. No changes have been made to the product performance specifications, sterilization process, manufacturing processes or risk assessment; and
The intended use and fundamental scientific technology remains unchanged; and ●
. No new or different questions of safety or effectiveness are raised with the proposed modification.

The performance claim of contrast volume reduction is supported by AVERT System clinical trial data and raises no new or different questions of safety and effectiveness as compared to the predicate. Both the predicate and the Dye Vert System have the identical intended use (i.e. "controlled infusion of dye") and the performance claim does not affect its intended use. The application type, anatomical structure use, patient population and clinical setting remains unchanged. Inherent in the 'control of contrast' is ensuring that sufficient contrast is delivered to maintain adequate opacity during a procedure and simultaneously not creating a situation of excess risk (e.g. excess contrast or radiation exposure); as such, hazard analysis for contrast volume reduction performance and the study adverse event analysis demonstrates no new risk types or increased risk as compared to the predicate.

Summary of Non-Clinical Testing:

The DyeVert System design consists of standard luer lock connections, tubing, contrast diversion mechanism and a reservoir chamber. Performance specifications of the subject device remains unchanged from the previously cleared version. Bench testing was performed and/or leveraged to support this submission and results demonstrate the DyeVert System materials, design considerations and

{6}------------------------------------------------

manufacturing processes continue to meet product specifications and performance requirements. The following testing was successfully completed and/or leveraged within this submission:

. Device performance testing for high viscosity contrasts was leveraged and included flow rate, peak pressure, leak testing, contrast diversion, mechanical cycle testing and visual verifications to design specifications for specific contrasts and catheter configurations. Additional device performance testing for use with low viscosity contrasts was completed and included flow rate, peak pressure and contrast diversion. No additional testing was deemed necessary for low viscosity contrast use. All testing passed and demonstrated product performance met all prior established acceptance criteria.
Sterilization conditions have been validated and leveraged in accordance with ISO 11135-. 1:2007, Sterilization of health care products - Ethylene Oxide Part 1: Requirements for the development, validation, and routine control of a sterilization process for medical devices to provide a Sterility Assurance Level of 10-6. All testing passed.
. Packaging, shelf life and distribution testing was performed and leveraged. Distribution testing was conducted per ASTM D4169:2009 Standard Practice for Performance Testing of Shipping Containers and Systems. Testing included visual inspection, cycle testing, dye leak test, seal strength test and functional testing. All testing passed and demonstrated product performance met all prior established acceptance criteria. Packaging was deemed to be in compliance with ISO 11607 part 1 and 2:2006 Packaging for terminally sterilized medical devices. Seal strength testing was performed per ASTM F88-09 and seal integrity by dye penetration was performed per ASTM F1886-09. All testing passed.
. Biocompatibility testing was performed and leveraged in accordance with ISO 10993-1:2009 Biological Evaluation of Medical Devices – Part I: Evaluation and Testing. Testing included cytotoxicity, sensitization, irritation (intracutaneous reactivity), systemic toxicity and hemocompatibility. All testing passed and met prior established acceptance criteria.
. Simulated Use (Cath Lab) and Design Validation was performed and leveraged for injection pressure, contrast diversion and image analysis testing. Testing included an assessment of the ease of use, system set up and device priming ability (usability). Testing demonstrated no new or different question of safety or effectiveness.

{7}------------------------------------------------

No performance standards have been established under Section 514 of the Food, Drug and Cosmetic Act for angiographic injectors and syringes.

Clinical Testing:

Human clinical data was leveraged and analyzed in support of this traditional 510(k) pre-market notification for controlled reduction of contrast volumes. A prospective, randomized, multi-center clinical evaluation was conducted using the Osprey Medical AVERT™ Contrast Modulation System. Leveraging of the clinical data is appropriate due to the high-level similarities of the devices and bench testing the AVERT System represents worse case contrast percentage reduction across the full range of catheter/contrast configurations as compared to the DyeVert System. The study demonstrated a mean difference in contrast volume between the contrast modulation system and control group, achieving a relative and clinically significant contrast volume reduction, while maintaining adequate image quality and with no device related adverse events.

The clinical trial occurred with male and female subjects 18 years and older that were candidates for therapeutic percutaneous coronary intervention procedures with documented chronic kidney disease. The primary effectiveness endpoint was to demonstrate a mean reduction of contrast volume required in the treatment group as compared to the standard of care control group. The data demonstrated a non-normalized distribution of subjects with a mean reduction of 15.4% with a corresponding t-test p value of 0.0229. This corresponds to a 15.0% relative reduction of contrast volume used between the treatment and control groups. Specifically, diagnostic angiographic procedure demonstrated a 20.6% relative reduction and PCI angiographic procedures demonstrated a 17.2% relative reduction. There were no reported device related or unanticipated adverse events. For the sample size of 147 patients (treatment group), there was only one incident recorded as poor image quality related to the treatment device that resulted in the system being "shut off". The result was low prevalence (<1%) and supports the effectiveness of minimizing contrast volume used while maintaining image quality.

Statement of Equivalence:

The DyeVert™ Contrast Modulation System has identical intended use, technological characteristics and fundamental scientific technology as the predicate devices. Based on this and data collected in accordance with Osprey Medical Quality System Procedures in compliance with ISO 13485:2003 Medical Devices -Ouality management systems - requirements for regulatory purposes and EN ISO 14791:2012 Risk management for medical devices, the DyeVert System has been shown to be substantially equivalent under 21 CFR Part 807 subpart E.

Regulation Number and Section

§ 870.1650 Angiographic injector and syringe.

(a)
Identification. An angiographic injector and syringe is a device that consists of a syringe and a high-pressure injector which are used to inject contrast material into the heart, great vessels, and coronary arteries to study the heart and vessels by x-ray photography.(b)
Classification. Class II (special controls). The device, when it is a non-patient contacting balloon inflation syringe intended only to inflate/deflate balloon catheters and monitor pressure within the balloon, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.